HK1039483A1 - Bicycle pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation is use thereof - Google Patents

Bicycle pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation is use thereof

Info

Publication number
HK1039483A1
HK1039483A1 HK01107828A HK01107828A HK1039483A1 HK 1039483 A1 HK1039483 A1 HK 1039483A1 HK 01107828 A HK01107828 A HK 01107828A HK 01107828 A HK01107828 A HK 01107828A HK 1039483 A1 HK1039483 A1 HK 1039483A1
Authority
HK
Hong Kong
Prior art keywords
dihydropyrimidines
pyrimidines
bicyclic
bicycle
inhibitors
Prior art date
Application number
HK01107828A
Other languages
English (en)
Inventor
Ellen Myra Dobrusin
James Marino Hamby
James Bernard Kramer
Mel Conrad Schroeder
Howard Daniel Hollis Showalter
Peter Toogood
Susanne A Trumpp-Kallmeyer
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26775058&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1039483(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of HK1039483A1 publication Critical patent/HK1039483A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK01107828A 1998-05-26 2001-11-08 Bicycle pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation is use thereof HK1039483A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8670898P 1998-05-26 1998-05-26
US12615899P 1999-03-25 1999-03-25
PCT/US1999/010187 WO1999061444A2 (en) 1998-05-26 1999-05-10 Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation

Publications (1)

Publication Number Publication Date
HK1039483A1 true HK1039483A1 (en) 2002-04-26

Family

ID=26775058

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01107828A HK1039483A1 (en) 1998-05-26 2001-11-08 Bicycle pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation is use thereof

Country Status (29)

Country Link
US (1) US7501425B1 (zh)
EP (1) EP1080092B1 (zh)
JP (1) JP2002516327A (zh)
KR (1) KR20010043829A (zh)
CN (1) CN1138778C (zh)
AP (1) AP2000001964A0 (zh)
AT (1) ATE402177T1 (zh)
AU (1) AU763839B2 (zh)
BG (1) BG104960A (zh)
BR (1) BR9911590A (zh)
CA (1) CA2329703C (zh)
DE (1) DE69939168D1 (zh)
EA (1) EA003640B1 (zh)
EE (1) EE200000706A (zh)
ES (1) ES2310039T3 (zh)
GE (1) GEP20033093B (zh)
HK (1) HK1039483A1 (zh)
HR (1) HRP20000799A2 (zh)
HU (1) HUP0102514A3 (zh)
ID (1) ID27589A (zh)
IL (1) IL139599A0 (zh)
IS (1) IS5687A (zh)
NO (1) NO20005928L (zh)
NZ (1) NZ508268A (zh)
PL (1) PL344248A1 (zh)
SK (1) SK17532000A3 (zh)
TR (1) TR200003429T2 (zh)
WO (1) WO1999061444A2 (zh)
YU (1) YU73300A (zh)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1080092B1 (en) 1998-05-26 2008-07-23 Warner-Lambert Company LLC Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
NZ510760A (en) * 1998-10-23 2003-08-29 F Bicyclic nitrogen heterocycles
KR100523120B1 (ko) 1999-10-21 2005-10-20 에프. 호프만-라 로슈 아게 Ｐ38 단백질 키나제 저해제로서 헤테로알킬아미노-치환된이환 질소 헤테로환
CZ20021743A3 (cs) * 1999-10-21 2002-08-14 F. Hoffmann-La Roche Ag Bicyklické dusíkové heterocykly substituované alkylaminoskupinou jako inhibitory P38 proteinkinázy
MXPA02005989A (es) 2000-01-24 2002-10-23 Warner Lambert Co Agentes antibacteriales de 3-aminoquinazolin-2,4-diona.
PL356802A1 (en) * 2000-01-25 2004-07-12 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
US7053070B2 (en) 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
AR030053A1 (es) * 2000-03-02 2003-08-13 Smithkline Beecham Corp 1h-pirimido [4,5-d] pirimidin-2-onas y sales, composiciones farmaceuticas, uso para la fabricacion de un medicamento y procedimiento para producirlas
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
IL151480A0 (en) * 2000-03-06 2003-04-10 Warner Lambert Co 5-alkylpyrido[2,3-d] pyrimidines tyrosine kinase inhibitors
CN1275964C (zh) * 2000-08-31 2006-09-20 霍夫曼-拉罗奇有限公司 作为细胞增殖抑制剂的7－氧代吡啶并嘧啶
US6506749B2 (en) 2000-08-31 2003-01-14 Syntex (U.S.A.) Llc 7-oxo-pyridopyrimidines (I)
CZ20031125A3 (cs) 2000-10-23 2003-10-15 Smithkline Beecham Corporation Nové sloučeniny
GB0029015D0 (en) 2000-11-28 2001-01-10 Univ London Medical device
WO2002060382A2 (en) 2001-01-19 2002-08-08 Smithkline Beecham Corporation Novel compounds and uses thereof
ATE305303T1 (de) 2001-02-12 2005-10-15 Hoffmann La Roche 6-substituierte pyridopyrimidine
US7105667B2 (en) 2001-05-01 2006-09-12 Bristol-Myers Squibb Co. Fused heterocyclic compounds and use thereof
MXPA03010799A (es) 2001-05-30 2005-07-25 Warner Lambert Co Agentes antibacterianos.
CN101001857B (zh) * 2002-01-22 2011-06-22 沃尼尔·朗伯有限责任公司 2-(吡啶-2-基氨基)-吡啶并[2,3-d]嘧啶-7-酮
US7176310B1 (en) 2002-04-09 2007-02-13 Ucb Sa Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents
PL373339A1 (en) 2002-04-19 2005-08-22 Smithkline Beecham Corporation Novel compounds
US7196090B2 (en) 2002-07-25 2007-03-27 Warner-Lambert Company Kinase inhibitors
ATE374201T1 (de) 2002-08-06 2007-10-15 Hoffmann La Roche 6-alkoxypyridopyrimidine als inhibitoren der p-38-map-kinase
US7084270B2 (en) * 2002-08-14 2006-08-01 Hoffman-La Roche Inc. Pyrimido compounds having antiproliferative activity
US7112676B2 (en) * 2002-11-04 2006-09-26 Hoffmann-La Roche Inc. Pyrimido compounds having antiproliferative activity
TW200413381A (en) 2002-11-04 2004-08-01 Hoffmann La Roche Novel amino-substituted dihydropyrimido [4,5-d]pyrimidinone derivatives, their manufacture and use as pharmaceutical agents
DE602004021558D1 (de) * 2003-01-17 2009-07-30 Warner Lambert Co 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation
RU2350617C2 (ru) 2003-04-10 2009-03-27 Ф.Хоффманн-Ля Рош Аг Пиримидиновые соединения, обладающие свойствами селективного ингибирования активности кдр и фрфр
DE10325133A1 (de) * 2003-06-04 2004-12-23 Bayer Cropscience Ag Triazolopyrimidine
CA2533774A1 (en) * 2003-07-29 2005-02-10 Irm Llc Compounds and compositions as protein kinase inhibitors
ATE356124T1 (de) 2003-11-13 2007-03-15 Hoffmann La Roche Hydroxyalkylsubstituierte pyrido-7-pyrimidin-7- one
JP4812763B2 (ja) * 2004-05-18 2011-11-09 ライジェル ファーマシューティカルズ， インコーポレイテッド シクロアルキル置換ピリミジンジアミン化合物およびそれらの用途
CA2576818A1 (en) 2004-08-31 2006-03-09 F. Hoffmann-La Roche Ag Amide derivatives of 3-phenyl dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents
US7494993B2 (en) 2004-08-31 2009-02-24 Hoffmann-La Roche Inc. Amide derivatives of 7-amino-3-phenyl-dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents
WO2006065703A1 (en) 2004-12-13 2006-06-22 Sunesis Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
EA200702073A1 (ru) 2005-03-25 2008-12-30 Глэксо Груп Лимитед Способ получения пиридо[2,3-d]пиримидин-7-оновых и 3,4-дигидропиримидо[4,5-d]пиримидин-2(1н)-оновых производных
JP2008535822A (ja) 2005-03-25 2008-09-04 グラクソ グループ リミテッド 新規化合物
AR053346A1 (es) 2005-03-25 2007-05-02 Glaxo Group Ltd Compuesto derivado de 8h -pirido (2,3-d) pirimidin -7 ona 2,4,8- trisustituida composicion farmaceutica y uso para preparar una composicion para tratamiento y profilxis de una enfermedad mediada por la quinasa csbp/ rk/p38
UY29439A1 (es) 2005-03-25 2006-10-02 Glaxo Group Ltd Nuevos compuestos
ATE439361T1 (de) 2006-01-31 2009-08-15 Hoffmann La Roche 7h-pyridoä3,4-düpyrimidin-8-one, ihre herstellung und ihre verwendung als proteinkinaseinhibitoren
EP2168966B1 (en) * 2007-06-15 2016-09-28 Msd K.K. Bicycloaniline derivative
GEP20125718B (en) 2008-02-01 2012-12-25 Takeda Pharmaceuticals Co Oxim derivatives as hsp90 inhibitors
CA2745970A1 (en) 2008-12-12 2010-06-17 Msd K.K. Dihydropyrimidopyrimidine derivative
CA2745959A1 (en) * 2008-12-12 2010-06-17 Msd K.K. Dihydropyrimidopyrimidine derivatives
EP3828185A3 (en) * 2009-01-06 2021-09-01 Dana Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
EP2401281A4 (en) * 2009-02-25 2012-08-15 Msd Kk PYRIMIDINPYRIMIDOINDAZOLDERIVAT
SA111320200B1 (ar) * 2010-02-17 2014-02-16 ديبيوفارم اس ايه مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
EA022527B1 (ru) * 2010-08-05 2016-01-29 Темпл Юниверсити - Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн 2-ЗАМЕЩЕННЫЕ-8-АЛКИЛ-7-ОКСО-7,8-ДИГИДРОПИРИДО[2,3-d]ПИРИМИДИН-6-КАРБОНИТРИЛЫ И ИХ ПРИМЕНЕНИЕ
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
FI2699553T3 (fi) 2011-04-22 2024-01-24 Signal Pharm Llc Substituoituja diaminokarboksamidi- ja diaminokarbonitriilipyrimidiinejä, niiden koostumuksia ja niitä käyttäviä hoitomenetelmiä
US9079929B2 (en) 2011-10-14 2015-07-14 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
SI2766346T1 (sl) 2011-10-14 2017-05-31 Bristol-Myers Squibb Company Substituirane tetrahidroizokinolinske spojine kot faktor xia inhibitorji
CN103987697B (zh) 2011-10-14 2017-04-26 百时美施贵宝公司 作为因子xia抑制剂的取代的四氢异喹啉化合物
SG10201610416TA (en) * 2012-06-13 2017-01-27 Incyte Corp Substituted tricyclic compounds as fgfr inhibitors
PT2872491T (pt) * 2012-07-11 2021-08-05 Blueprint Medicines Corp Inibidores do recetor do fator de crescimento de fibroblastos
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
WO2014059202A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
US9403774B2 (en) 2012-10-12 2016-08-02 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
TR201807316T4 (tr) 2012-10-12 2018-06-21 Squibb Bristol Myers Co Bir faktör XIa inhibitörünün kristalli formları.
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
KR102219695B1 (ko) 2013-03-15 2021-02-25 셀젠 카르 엘엘씨 헤테로아릴 화합물 및 이의 용도
UA120248C2 (uk) 2013-03-15 2019-11-11 Селджен Кар Ллс Гетероарильні сполуки та їх застосування
AR095464A1 (es) 2013-03-15 2015-10-21 Celgene Avilomics Res Inc Compuestos de heteroarilo y usos de los mismos
US9738655B2 (en) 2013-03-25 2017-08-22 Bristol-Myers Squibb Company Tetrahydroisoquinolines containing substituted azoles as factor XIa inhibitors
SI2986610T1 (en) * 2013-04-19 2018-04-30 Incyte Holdings Corporation Bicyclic heterocycles as inhibitors of FGFR
WO2015006492A1 (en) * 2013-07-09 2015-01-15 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease
RU2715708C2 (ru) 2013-10-18 2020-03-03 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Ингибиторы fgfr4
JP6458023B2 (ja) 2013-10-25 2019-01-23 ブループリント メディシンズ コーポレイション 繊維芽細胞成長因子受容体の阻害剤
EP3082819B1 (en) 2013-12-20 2020-06-17 Signal Pharmaceuticals, LLC Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith
TWI688564B (zh) 2014-01-31 2020-03-21 美商必治妥美雅史谷比公司 作為凝血因子ｘｉａ抑制劑之具有雜環p2'基團之巨環化合物
NO2760821T3 (zh) 2014-01-31 2018-03-10
CN103880861B (zh) * 2014-02-21 2016-02-03 温州医科大学 一种作用于FGF受体的4,6-二甲基-噁唑并[5,4-d]嘧啶-5,7（4H,6H）-二酮衍生物
ES2714283T3 (es) 2014-09-04 2019-05-28 Bristol Myers Squibb Co Macrociclos de diamida que son inhibidores de FXIa
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MX2020004108A (es) 2015-02-20 2022-01-03 Incyte Corp Heterociclos biciclicos como inhibidores de receptores del factor de crecimiento fibroblastico (fgfr).
SG10201810057UA (en) 2015-04-14 2018-12-28 Eisai R&D Man Co Ltd Crystalline fgfr4 inhibitor compound and uses thereof
JP7372740B2 (ja) 2016-05-10 2023-11-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 細胞生存性及び／又は細胞増殖を低減するための薬物の組み合わせ
CN107459519A (zh) * 2016-06-06 2017-12-12 上海艾力斯医药科技有限公司 稠合嘧啶哌啶环衍生物及其制备方法和应用
CN110225914A (zh) * 2016-07-05 2019-09-10 布罗德研究所股份有限公司 双环脲激酶抑制剂及其用途
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
CA3054809A1 (en) 2017-02-28 2018-09-07 The General Hospital Corporation Uses of pyrimidopyrimidinones as sik inhibitors
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
TW201946630A (zh) 2018-05-04 2019-12-16 美商英塞特公司 Fgfr抑制劑之鹽
WO2019213544A2 (en) 2018-05-04 2019-11-07 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
IL291901A (en) 2019-10-14 2022-06-01 Incyte Corp Bicyclyl heterocycles as fgr suppressors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021113462A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
EP4175719A1 (en) 2020-07-02 2023-05-10 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
AR125273A1 (es) 2021-02-25 2023-07-05 Incyte Corp Lactamas espirocíclicas como inhibidores de jak2 v617f
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2949466A (en) 1958-03-04 1960-08-16 Parke Davis & Co Pyrimidine compounds and means of producing the same
ES338687A1 (es) 1966-04-06 1968-04-01 Monsanto Co Procedimiento para obtener composiciones de fluidos funcio-nales.
US3912723A (en) 1971-03-29 1975-10-14 Pfizer 2-Phenyl-as-triazine-3,5(2H,4H)diones
DE3062268D1 (en) 1979-06-14 1983-04-14 Wellcome Found Alkoxybenzylpyridopyrimidines, methods for their preparation and pharmaceutical formulations thereof
US4425346A (en) 1980-08-01 1984-01-10 Smith And Nephew Associated Companies Limited Pharmaceutical compositions
JPS60226882A (ja) 1984-04-24 1985-11-12 Nippon Zoki Pharmaceut Co Ltd 新規ピリミドピリミジン誘導体
EP0278686A1 (en) * 1987-02-07 1988-08-17 The Wellcome Foundation Limited Pyridopyrimidines methods for their preparation and pharmaceutical formulations thereof
WO1992020642A1 (en) * 1991-05-10 1992-11-26 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5654307A (en) 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
AU701127B2 (en) 1994-10-27 1999-01-21 Merck & Co., Inc. Muscarine antagonists
TJ342B (en) * 1994-11-14 2002-10-06 Warner Lambert Co Derivatives of 6-aryl pyrido Ä2,3-dÜ pyrimidines and naphthyridines pharmaceutical composition possess inhibiting effect of cellular proliferation pr ovoking protein tyrosine kinase and method of inhibiting cellular proliferation
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
EP0892789B2 (en) 1996-04-12 2009-11-18 Warner-Lambert Company LLC Irreversible inhibitors of tyrosine kinases
EP0964864B1 (en) * 1997-02-05 2008-04-09 Warner-Lambert Company LLC Pyrido 2,3-d pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
BR9811956B1 (pt) * 1997-08-20 2010-06-01 naftiridinonas e composição farmacêutica compreendendo as mesmas.
JP4038624B2 (ja) 1997-11-29 2008-01-30 日本農薬株式会社 縮合複素環誘導体及びその中間体並びに有害生物防除剤
EP1080092B1 (en) 1998-05-26 2008-07-23 Warner-Lambert Company LLC Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
NZ510760A (en) 1998-10-23 2003-08-29 F Bicyclic nitrogen heterocycles
CZ20021743A3 (cs) 1999-10-21 2002-08-14 F. Hoffmann-La Roche Ag Bicyklické dusíkové heterocykly substituované alkylaminoskupinou jako inhibitory P38 proteinkinázy
KR100523120B1 (ko) 1999-10-21 2005-10-20 에프. 호프만-라 로슈 아게 Ｐ38 단백질 키나제 저해제로서 헤테로알킬아미노-치환된이환 질소 헤테로환
AR030053A1 (es) 2000-03-02 2003-08-13 Smithkline Beecham Corp 1h-pirimido [4,5-d] pirimidin-2-onas y sales, composiciones farmaceuticas, uso para la fabricacion de un medicamento y procedimiento para producirlas

Also Published As

Publication number Publication date
AP2000001964A0 (en) 2000-12-31
EP1080092B1 (en) 2008-07-23
IL139599A0 (en) 2002-02-10
AU4073499A (en) 1999-12-13
DE69939168D1 (de) 2008-09-04
CN1302301A (zh) 2001-07-04
EP1080092A2 (en) 2001-03-07
JP2002516327A (ja) 2002-06-04
EE200000706A (et) 2002-06-17
WO1999061444A2 (en) 1999-12-02
BG104960A (en) 2001-10-31
NZ508268A (en) 2004-02-27
PL344248A1 (en) 2001-10-22
CN1138778C (zh) 2004-02-18
NO20005928D0 (no) 2000-11-23
ES2310039T3 (es) 2008-12-16
HRP20000799A2 (en) 2001-06-30
AU763839B2 (en) 2003-07-31
EA200001171A1 (ru) 2001-06-25
HUP0102514A2 (hu) 2001-11-28
WO1999061444A3 (en) 2000-02-03
CA2329703C (en) 2005-12-20
TR200003429T2 (tr) 2001-07-23
EA003640B1 (ru) 2003-08-28
GEP20033093B (en) 2003-10-27
HUP0102514A3 (en) 2002-03-28
KR20010043829A (ko) 2001-05-25
US7501425B1 (en) 2009-03-10
ATE402177T1 (de) 2008-08-15
SK17532000A3 (sk) 2002-08-06
IS5687A (is) 2000-10-27
NO20005928L (no) 2000-11-23
ID27589A (id) 2001-04-12
YU73300A (sh) 2003-08-29
CA2329703A1 (en) 1999-12-02
BR9911590A (pt) 2001-02-13

Similar Documents

Publication Publication Date Title
HK1039483A1 (en) Bicycle pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation is use thereof
HU0003386D0 (en) Use of crf antagonists
EP1018987A4 (en) NEO-CARTILAGE AND ITS METHODS OF USE
HK1036801A1 (en) Pyrrolo(2,3-d)pyrimidine compounds, composition and use there of
EG24027A (en) Pyrrolotriazine inhibitors of kinases
SI1475377T1 (sl) Indolni derivati in njihova uporaba kot inhibitorji fosfodiesteraze 4
IL130900A0 (en) Atropisomers of 3-aryl-4(3H)- quinazolinones and their use as ampa-receptor antagonsts
IL130181A0 (en) Substituted pyrimidone and pyridone compounds and methods of use
IL161258A0 (en) Heterocyclic compounds and methods of use
PL331221A1 (en) Heteroaromatic bicyclic compounds as inhibitors of propteinous tyrosine kinase
AU4520801A (en) Novel substituted phenanthridinones and methods of use thereof
PL333505A1 (en) Benzamido-aldehydes and their application as inhibitors of cysteinic proteases
HK1043113A1 (zh) 端粒酶抑制劑及其使用方法
PL337645A1 (en) Novel amidine derivatives and their application as thrombosin inhibitors
HU9800112D0 (en) Biphenyl-sulfonyl-substituted heterocyclic compounds of fife-membered ring, their production and use
AU3786299A (en) Novel serotonin-like 9-substituted hypoxanthine and methods of use
PL325122A1 (en) Bicyclic derivatives of 4-aralkylamino pyrididine as inhibitors of thyrosinic kinase
MXPA02000779A (es) Factor de activacion de la citocina altamente purificada y metodos de uso.
PL361733A1 (en) Sulfamidothienopyrimidines and the use of the same as phosphodiesterase v inhibitors
AU2517399A (en) Utilization of substituted sulfonamides as antiviral agents and novel substances
IL130180A0 (en) Substituted pyrimidine compounds and their use
AU1522400A (en) Substituted pyrimidine compositions and methods of use
HK1066804A1 (en) Derivatives of indole and their use as phosphodiesterase 4 inhibitors
EP1137412A4 (en) SUBSTITUTED NITROGEN HETEROCYCLIC COMPOUNDS AND THEIR THERAPEUTIC USE
GB9600559D0 (en) Use of chemokines

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20080510